BioCentury | Oct 20, 2016
Distillery Therapeutics

Cancer

...scrambled shRNA. Next steps could include testing SET inhibition in models of other p53-mutant cancer. Oncotide Pharmaceuticals Inc....
...Sept. 14, 2016 doi:10.1038/nature19759 CONTACT: Wei Gu, Columbia University , New York, N.Y. email: wg8@cumc.columbia.edu Esme Gaisford OP449 Oncotide Pharmaceuticals Inc. SET...
BioCentury | Jun 23, 2014
Emerging Company Profile

Dual: Multi-pronged attack

...YE15. At least one company is working on an indirect activator of PP2A in cancer. Oncotide Pharmaceuticals Inc....
...York, N.Y. Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Oncotide Pharmaceuticals Inc....
BioCentury | Oct 3, 2013
Distillery Therapeutics

Indication: Cancer

...markets the sphingosine 1-phosphate receptor agonist Gilenya to treat relapsing forms of multiple sclerosis (MS). Oncotide Pharmaceuticals Inc....
BioCentury | Jul 23, 2012
Emerging Company Profile

Oncotide: SETting up phosphatases

...than inhibiting kinases to restore normal phosphorylation and reduce the signaling of up-regulated oncogenic pathways, Oncotide...
...the enzymatic activity of phosphatases has proven difficult. No phosphatase activators are on the market. Oncotide...
...homolog ( MYC ; c-MYC ) pathways, both of which are associated with poor prognosis. Oncotide...
BioCentury | Sep 1, 2011
Distillery Therapeutics

Indication: Cancer

...studies to move OP499 into clinical trials for hematologic malignancies. OP449, a SET inhibitor from Oncotide Pharmaceuticals Inc....
...online Aug. 15, 2011; doi:10.1182/blood-2011-04-351072 Contact: Dale J. Christensen, Oncotide Pharmaceuticals Inc., Research Triangle Park, N.C. e-mail: dchristensen@oncotide.com BC...
BioCentury | Apr 11, 2011
Company News

Cognosci, Oncotide deal

...Oncotide an exclusive license for IP covering its cancer pipeline, and provided undisclosed seed financing. Oncotide's...
...tumors in 2012. Further terms were not disclosed. Cognosci Inc. , Research Triangle Park, N.C. Oncotide Pharmaceuticals Inc....
Items per page:
1 - 6 of 6
BioCentury | Oct 20, 2016
Distillery Therapeutics

Cancer

...scrambled shRNA. Next steps could include testing SET inhibition in models of other p53-mutant cancer. Oncotide Pharmaceuticals Inc....
...Sept. 14, 2016 doi:10.1038/nature19759 CONTACT: Wei Gu, Columbia University , New York, N.Y. email: wg8@cumc.columbia.edu Esme Gaisford OP449 Oncotide Pharmaceuticals Inc. SET...
BioCentury | Jun 23, 2014
Emerging Company Profile

Dual: Multi-pronged attack

...YE15. At least one company is working on an indirect activator of PP2A in cancer. Oncotide Pharmaceuticals Inc....
...York, N.Y. Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Oncotide Pharmaceuticals Inc....
BioCentury | Oct 3, 2013
Distillery Therapeutics

Indication: Cancer

...markets the sphingosine 1-phosphate receptor agonist Gilenya to treat relapsing forms of multiple sclerosis (MS). Oncotide Pharmaceuticals Inc....
BioCentury | Jul 23, 2012
Emerging Company Profile

Oncotide: SETting up phosphatases

...than inhibiting kinases to restore normal phosphorylation and reduce the signaling of up-regulated oncogenic pathways, Oncotide...
...the enzymatic activity of phosphatases has proven difficult. No phosphatase activators are on the market. Oncotide...
...homolog ( MYC ; c-MYC ) pathways, both of which are associated with poor prognosis. Oncotide...
BioCentury | Sep 1, 2011
Distillery Therapeutics

Indication: Cancer

...studies to move OP499 into clinical trials for hematologic malignancies. OP449, a SET inhibitor from Oncotide Pharmaceuticals Inc....
...online Aug. 15, 2011; doi:10.1182/blood-2011-04-351072 Contact: Dale J. Christensen, Oncotide Pharmaceuticals Inc., Research Triangle Park, N.C. e-mail: dchristensen@oncotide.com BC...
BioCentury | Apr 11, 2011
Company News

Cognosci, Oncotide deal

...Oncotide an exclusive license for IP covering its cancer pipeline, and provided undisclosed seed financing. Oncotide's...
...tumors in 2012. Further terms were not disclosed. Cognosci Inc. , Research Triangle Park, N.C. Oncotide Pharmaceuticals Inc....
Items per page:
1 - 6 of 6